Hememics Biotechnologies: Revolutionizing Diagnostics With “Lab-in-a-Hand”
Overview – Disrupting Outdated Diagnostics
Hememics Biotechnologies, headquartered in Gaithersburg, MD, is revolutionizing point‑of‑care testing with its innovative handheld reader and disposable plastic chips. Capable of analyzing saliva, water, urine, or blood within five minutes, their platform simultaneously detects small molecules and protein targets—delivering rapid, reliable results at a fraction of traditional lab costs.
Built on graphene biosensor technology, Hememics addresses critical shortcomings in legacy diagnostics—many of which rely on methods that haven’t seen meaningful advancement in 40–50 years.
Why Investors Should Pay Attention
Proven Traction & Credibility
In July 2025, Hememics secured a $2 million Seed 2 round led by TEDCO, supported by returning and strategic investors.
Earlier, in March 2025, TEDCO had also injected $250,000 via its Venture Funds—building further confidence in the company’s innovation and execution.
As of now, total capital raised since inception stands in the range of $7.5 million, with some estimates rounding to $10.2 million, backed by investors like DMV Angel Group, American Vietnamese Investment Partners, and Inova Health System.
These investments reflect growing institutional support and trust in Hememics’ commercial potential.
High-Impact, Multi‑Industry Applications
Biodefense: On‑site, rapid detection of biotoxins such as ricin and botulinum—crucial for military and emergency protocols.
Agriculture: Field screening for herbicides like glyphosate and dicamba—offering accuracy that lateral flow tests struggle to match.
Drug Monitoring: A user-friendly system for drug panels in urine, with clear, digital readouts—addressing gaps in current testing standards.
Healthcare: Rapid protein and small‑molecule diagnostics in emergency and clinical trial settings—empowering faster, more informed decision‑making.
Scalable, Cost‑Effective Innovation
Graphene-based technology enables ultra-sensitive, multiplexed detection in a portable form factor, delivering lab-grade performance with scalability and low unit costs.
Investment Opportunity via Community Equity Partners
Accredited investors can participate in Hememics through Community Equity Partners (CEP). Structurally, this is facilitated via Special Purpose Vehicles (SPVs), and CEP will manage due diligence and ongoing investor communications.
Your Next Move: Seize the Opportunity
Ready to invest in the future of diagnostics? Here’s how:
Fill out the CEP interest form to indicate your accredited status and preferred investment level.
Receive detailed diligence materials, tailored SPV structure, and exclusive company updates.
Get involved early as Hememics scales manufacturing, expands market reach, and accelerates R&D.
Act Now—Partner With a Breakthrough Innovator
Hememics is poised to transform multiple critical sectors through affordable, powerful diagnostics. Join discerning investors backing cutting-edge biotech—invest today to help shape tomorrow.
Note: This is not financial advice nor an offering of securities. CEP urges prospective investors to seek professional counsel tailored to your individual financial objectives.
